Shattuck Labs expects to price 10M shares in IPO at $14-$16

• Oncology biotech, Shattuck Labs (STTK) to issue 10M shares at an initial offering price range of $14-$16.
• Underwriters' over-allotment is an additional 1.5M common shares.
• With 38.1M shares outstanding, the pricing values the company at up to $609.3M.
• The company is currently conducting a Phase 1 trial of SL-172154 for ovarian cancer, with initial data expected in the 2H21. 
• The company intends to use the net proceeds together with existing cash and cash equivalents and short term investments: to advance SL-172154 through the completion of ongoing and planned Phase 1 clinical trials and to commence a Phase 2 clinical program; to advance SL-279252 through the completion of ongoing Phase 1 clinical trial; and to develop and advance additional product candidates derived from platforms through IND-enabling studies and to commence Phase 1 clinical trials.
• The company has booked $11M in collaboration revenue for the 12 months ended June 30, 2020.
• The following table highlights company's two clinical-stage assets that have been derived from ARC platform: 
• Source
• https://seekingalpha.com/news/3619768-shattuck-labs-expects-to-price-10m-shares-in-ipo-14-16